Does Recent Drug Approval News Signal Opportunity in Novo Nordisk for 2025?

• Wondering whether Novo Nordisk is a smart buy, overpriced, or quietly undervalued? You are in the right place if you want to look beyond the headlines and see what value the numbers reveal.
• Shares have seesawed lately, with a 3.7% bump in the past week. However, they are still down 12.6% over 30 days and are in the red by 42.6% year-to-date.
• The volatility has been driven by a slew of recent news, including updates on new drug approvals and partnerships with major healthcare providers. These headlines have sparked fresh debate about the company's long-term prospects and how the recent developments could influence growth.
• Novo Nordisk currently scores a 5 out of 6 on our latest valuation checks, suggesting the stock could be undervalued on several key measures. Next, we will break down the main valuation approaches used by analysts. For the clearest picture of value, be sure to stick around for our closing insights.

Find out why Novo Nordisk's -52.0% return over the last year is lagging behind its peers.

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) model is a common valuation approach that estimates a company's intrinsic worth by projecting its future free cash flows and discounting them back to today's value. This helps investors gauge what a business might be worth now, based on the cash it will likely generate over time.

For Novo Nordisk, the latest model uses a 2 Stage Free Cash Flow to Equity approach. The company currently generates DKK 67.6 billion in free cash flow. Analyst estimates project solid growth, with free cash flow expected to reach DKK 129.5 billion by 2029. Beyond the next five years, long-term projections by Simply Wall St indicate a continued upward trend for the following decade.

Taking these cash flow projections into account, the DCF model suggests an intrinsic share value of $160.49. This figure implies the stock is trading at a 68.7% discount relative to its estimated fair value, which signals that shares may be significantly undervalued on a cash flow basis.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 68.7%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk.

Approach 2: Novo Nordisk Price vs Earnings

The Price-to-Earnings (PE) ratio is a popular way to value profitable companies like Novo Nordisk, as it compares the current share price to the company’s earnings. This makes it a quick way to gauge how much investors are willing to pay per dollar of profit, offering a useful approximation of market sentiment toward the business’s future prospects.

Growth expectations and risk both play crucial roles in what counts as a “normal” or “fair” PE ratio. Companies with fast-growing earnings or more stability typically trade at higher multiples, while slower growth or higher risks tend to mean a lower PE is justified. For reference, Novo Nordisk’s current PE stands at 13.75x, while the industry average is 18.14x and the average for close peers is 15.53x. This suggests Novo is trading at a discount relative to the broader pharmaceuticals sector and its direct peers.

Simply Wall St’s “Fair Ratio” takes this a step further by estimating the PE ratio that is justified given Novo Nordisk’s earnings growth, profit margins, industry positioning, company size, and risk profile. Unlike a simple industry or peer comparison, the Fair Ratio reflects the company’s unique business mix and future outlook rather than only how similar companies are priced. For Novo Nordisk, the Fair Ratio is 33.11x, much higher than both its current PE and industry benchmarks, which means the market may be undervaluing the stock’s earnings potential in the context of its strengths and outlook.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1404 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives. Narratives are a dynamic tool that lets you frame your investment thesis by connecting the story you believe about Novo Nordisk to the numbers you expect it can deliver, such as future revenue growth, profit margins, and ultimately your idea of fair value.

Unlike static models, a Narrative links your outlook on the business with a financial forecast and then calculates a fair value based on your expectations. Narratives make this process accessible for everyone and can be found on Simply Wall St’s platform, inside the Community page used by millions of investors worldwide.

This approach equips you to decide when to buy or sell by directly comparing the up-to-date Fair Value you calculate, based on your Narrative, to the current share price. As market news or earnings are released, Narratives update in real time, keeping your outlook and valuation relevant without extra effort.

For example, one optimistic Narrative for Novo Nordisk projects a Fair Value as high as $160 per ADR based on continued pipeline momentum and robust earnings. A more cautious view, factoring in sluggish prescription trends and new policy risks, places Fair Value closer to $70 per ADR.

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com